Investigational Agent 1 is a new type of medication being tested to see if it is safe and can be tolerated by patients. It is designed to target specific changes in the cells of children with certain blood cancers that have come back or are not responding to treatment. The goal is to find out if this medication can help stop the cancer cells from growing.

Investigational Agent 2 is another new medication being studied in this trial. It works by focusing on particular genetic changes in the cancer cells of children with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers want to see if this medication can effectively slow down or stop the growth of these cancer cells.

Acute Lymphoblastic Leukemia – This is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature white blood cells, known as lymphoblasts. It progresses rapidly, leading to an accumulation of these cells in the bone marrow, which interferes with the production of normal blood cells. As the disease advances, it can spread to other parts of the body, including the lymph nodes, liver, spleen, and central nervous system. Symptoms may include fatigue, fever, frequent infections, and easy bruising or bleeding. The disease is most common in children but can also occur in adults.

Lymphoblastic Lymphoma – This is a rare type of non-Hodgkin lymphoma that primarily affects the lymphatic system, which is part of the immune system. It is characterized by the rapid growth of immature lymphocytes, which are a type of white blood cell. The disease can present as a mass in the chest, neck, or other areas of the body, and may cause symptoms such as swelling, difficulty breathing, or chest pain. As it progresses, it can spread to the bone marrow and other organs. Lymphoblastic lymphoma is closely related to acute lymphoblastic leukemia and shares many clinical features.